Benjamin Kaffenberger, MD

1. Kaffenberger, BH. Panniculitis. In: Dean S, Satiani B, eds.  Color Atlas and Synopsis of Vascular Medicine, 1st ed.  New York, NY: McGraw-Hill; 2011. 

2. McKinley G, Maher M, Gru AA, Kaffenberger, BH. Histopathology of cutaneous adverse reactions to oncologic therapeutics. In: Gru AA ed. Hematopathology of the skin, 1st ed. New York, NY: Springer Press 2015.

3. Kaffenberger BH, Bechtel MA, Porcu PG. Chapter 2: Treatment of Cutaneous T-cell Lymphoma. In: Magro CM, Crowson AN, Mihm MC eds. The Cutaneous Lymphoid Proliferations:  A comprehesive textbook of lymphocytic infiltrates of the skin 2nd ed. New York, NY: Wiley Medical Press. 2016. 

4. Kaffenberger BH, Jaglowski S. Dermal and Subcutaneous chronic Graft-versus-Host disease. In: Cotliar J, ed. Atlas of Graft-versus-Host disease. New York, NY: Springer Medical 2017. 

1. M11-313 – Phase 3 study for the use of Adalimumab for hidradenitis Suppurativa. PI: Henry Wong, MD, PhD. Sponsor: Abbvie. Role: Subinvestigator

2. SHP-141-001 – Phase 1B Dose escalation study for topical histone deacetylase inhibitor in stage IA – IIA CTCL. PI: Henry Wong, MD, PhD. Sponsor: Shape Pharmaceuticals. Role: Subinvestigator

3. AMAGINE-2 – Phase 3 study for Brodalumab compared with placebo and ustekinumab in psoriasis. PI Henry Wong, MD, PhD. Sponsor Amgen. Role: Subinvestigator

4. pStellar – Phase 4 study for dosing for ustekinumab in patients with moderate to severe psoriasis. PI: Henry Wong, MD, PhD. Sponsor: Janssen Pharmaceuticals. Role: Subinvestigator

5. OSU 12168: Prospective, randomized, controlled, partially blinded, skin photobiological clinical study of the efficacy and safety of a sunscreen product as skin protector against porfimer sodium-induced phototoxicity to visible light. Role: Subinvestigator

6. PCYC-1129/OSU-14094: A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease. Sponsor: Pharmacyclics. Role: Subinvestigator 

7. OSU14004: A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal . Role Sub-I. Sponsor: Novartis.

8. OSU-14287: A Multicenter Phase I dose-finding and preliminary efficacy study of the histone deacetylase inhibitor romidepsin (Istodax®) in combination with doxorubicin HCl liposomal (or Doxil®) for the treatment of adults with relapsed or refractory T-cell lymphomas. Role: Co-investigator

9. XOMA X052171, and 172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum and open label follow-up. Role: PI

10. Celgene: A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Role: PI

11. OSU 2015H0134: The effect of teledermatology on length of hospital admission, length of stay, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic emergency department setting. Role: PI

12. XBiotech 2013-PT025: A Phase II Open Label Study of RA-18C3 in Subjects with Pyoderma Gangrenosum. Role PI. 

13. OSU 2015H0393: The effect of dermatology and teledermatology consultations on length of hospital admission, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic inpatient setting. Role: PI

14. Lilac: A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations. Role PI

15. IPI-145-02: A PHASE 1 STUDY OF IPI-145 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES. Role CO-I

16. BRF114144: A ROLLOVER STUDY TO PROVIDE CONTINUED TREATMENT WITH GSK2118436 TO SUBJECTS WITH BRAF MUTATION-POSITIVE TUMORS. Role CO-I. 

17. MO28295: A RANDOMIZED, DOUBLE-BLINDED, REGIMEN-CONTROLLED, PHASE II, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWO DIFFERENT VISMODEGIB REGIMENS IN PATIENTS WITH MULTIPLE BASAL CELL CARCINOMAS. Role CO-I. 

18. OSU2017H0045: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum. Investigator Initiated Trial. Role PI. $75,478

19. Veloce Biopharmaceuticals:  A multi-center, randomized, double-blind, vehicle-controlled, phase-2 trial to evaluate the efficacy and safety of two concentrations of topical povidone-iodine nail solution (VBP-926) for the treatment of chemotherapy-associated paronychia in cancer patients

• 11/2013-11/6: OSUCOM. Med 2 Host Defense Block: Inflammatory Skin Diseases Part 1 and Part 2. 
• 03/2008 – 06/2008 Division of Anatomy, Ohio State University - 201 Anatomy for Science Majors TA, 09/2007 - 09/2007  MEDPATH, Ohio State University - MCAT Facilitated Review Instructor
• 08/2007 - 11/2007 Division of Anatomy, Ohio State University Medical School Gross Anatomy TA, 
• 04/2007 - 07/2007 MEDPATH, Ohio State University 693 Immunology Course Instructor

1. Dermatology for Primary Care Providers. 6/20/13. Chalmers P. Wylie Columbus VA Medical                                       Center. Audience 80 primary and non-dermatology specialty physicians. 

2. A standardized letter of recommendation template for medical students applying to dermatology? 9/29/13 Association of Professors of Dermatology. 2013 Association of Professors of Dermatology Meeting, Chicago IL. Audience 200 dermatology chairs and program directors. 

3. Leprosy: A reason for why we volunteer at the free clinic. 10/26/13. Ohio Dermatologic Association Dr. Jerome R. Pomeranz Chief Resident Lectureship, 2013. Columbus OH. Audience 250 practicing Ohio Dermatologists, and APNs.

4. Graft-versus-Host Disease: Applications from dermatology. 3/5/2014. OSU Arthur G. James Cancer Hospital clinical and translational BMT meeting. Audience: Pediatric and adult hematologists, pathologists, and basic science researchers at OSU.

5. Pregnancy-associated AND other dermatoses of young women. 3/6/2014. OSU Wexner Medical Center, Maternal-Fetal Medicine lecture. Audience Maternal-Fetal medicine Fellows. 

6. Chief presentation. 5/21/14. Ohio State University Grand Rounds Presentation. 2014. Columbus, OH. Audience 40 practicing dermatologists and residents. 

7. Common Rashes in Primary Care. 10/23/14. OSU Wexner Medical Center and MedNET, live streaming. Columbus OH. Audience: Live and on-demand streaming to providers in over 150 countries. 

8. Unilesional Diagnosis for Primary Care Providers. 10/29/2014. OSU Wexner Medical Center Department of Family Medicine Grand Rounds. Columbus OH. Audience 50 resident and attendings. 

9. HIV and the Skin. 1/6/15. OSU Wexner Medical Center, division of Infectious Diseases afternoon conference (CME). Columbus OH. Audience 10 fellows and attendings.

10. Making rash decisions: Inflammatory skin disease. 1/21/15. OSU Wexner Medical Center, Department of Family Medicine Grand Rounds (CME). Columbus, OH. Audience: 60 Physicians

11. Mesenchymal Stem Cells and Graft-versus-Host Disease. 3/24/15. American Academy of Dermatology 73rd Annual Meeting (CME). San Francisco, CA. 

12. Dermatology Top 20. 9/8/15. OSU College of Nursing, Columbus, OH. Audience: 20 graduate nurses within primary care, adult/gerontology specialization. 

13. HIV Dermatology. 1-19-16. OSU Wexner Medical Center, division of Infectious Diseases afternoon conference (CME). Columbus OH. Audience 18 fellows and attendings.

14. Dermatology in the non-HIV setting for infectious disease physicians. 3/1/16. OSU Wexner Medical Center, division of Infectious Diseases afternoon conference (CME). Columbus OH. Audience 14 fellows and attendings.

15. Cutaneous Graft-versus-Host Disease. In course: Medical Dermatology. Course director Misha Rosenbach, MD. 3/7/16. American Academy of Dermatology 74th Annual Meeting (CME). Washington, D.C. 

16. Dermatologic Manifestations of PTEN Related Disorders. In course: Cowden syndrome and other PTEN-related disorders: a Patient-Oriented Symposium. 5/14/16. Columbus, OH. 

17. Dermatology and HIV. 6/26/16. Geriatric Research Education and Clinical Care Committee from the Cleveland VA. Cleveland, OH, with online audience members in NC, NH, VT, and WV. 

18. Boards-worthy topics in targeted and traditional oncologic agents. In: Ohio Dermatology Association Resident Day. 9/30/2016. Columbus, OH. Audience 40 Dermatology residents. 

19. Medical Dermatology MOC. Faculty.  In Ohio Dermatology Association Annual Meeting.  9/30/2016. Columbus, OH. Audience 100 Dermatology Attendings, residents, and Mid-levels.

20. A Rash of New Targeted Monoclonal Antibodies. Ohio Dermatology Association Annual Meeting. 10/2/2016. Columbus, Oh. Audience 200 Dermatology Attendings, residents, and mid-levels. 

21. General Dermatology and Drug Eruptions for the Generalist. Mount Nittany Update in Internal Medicine. 10/21/2016. State College, PA. Audience 250 Physicians, mid-levels, and students. 

22. Skin Disorders in Cancer Patients. Stephanie Spielman Breast Cancer Series Lecture. 11/8/16. Columbus, OH. Audience 15 Physicians, mid-levels, and physicians.  

23. Skin diseases associated with Climate Change in North America. In course: Outbreak! Public Health Threats in Dermatology. Course Director, Wingfield Rehmus, MD. 3/3/2017. American Academy of Dermatology 75th Annual Meeting (CME). Orlando, FL. 

24. Challenging Cases from Ohio State. In course: Finding Solutions to Difficult Cases. Course Director, Milan Anadkat, MD. 3/5/2017. American Academy of Dermatology 75th Annual Meeting (CME). Orlando, FL.

25. Dermatologic Emergencies and Urgencies. Ohio Valley Medical Center Combined Residency Grand Rounds. 6/22/17. Audience 30 Resident and Attending Physicians, Wheeling, WV. 

26. A Morphologic Approach to Dermatologic Urgencies and Emergencies. Ohio State University Wexner Medical Center Hospital Medicine Grand Rounds. 10/10/2017. Audience 40 attending physicians. Columbus, OH. 

27. Teaching and Learning Cases from Columbus. Marshfield Clinic Dermatology Resident Program, Marshfield WI. 10/12/2017. Audience 6 resident dermatologists. 

28. An Evidenced-Based Approach to the Morbilliform Eruption. William Schorr, MD Visiting Lectureship for the Marshfield Clinic Health System Dermatology Program. 10/12/2017. Audience 20 attending and resident dermatologists, Mohs surgeons, and dermatopathologists. Marshfield, WI

29. Climate Change and the Dermatologist:  Disease and Vector Changes in North America. Tennessee Society of Dermatology 2017 meeting. 11/4/2017. Audience: 150 attending and resident dermatologists, and midlevel providers through Tennessee, Mississippi, and Arkansas. Memphis, TN

30. Clinicopathologic Correlation in Hospital Dermatology. University of Virginia Pathology and Dermatology Grand Rounds. 11/7/2017. Audience 60 pathology and dermatology faculty, residents, and graduate students. Charlottesville, VA. 

31. Paradigm changes in Access to Dermatologic Care: Teledermatology and Hospital Dermatology. Ohio State University Wexner Medical Center Internal Medicine Grand Rounds. 1/11/2018. Audience: Internal Medicine Physicians, Residents, and Students with 80 in live attendance.  Columbus, OH. 

32. Teledermatology for Medicaid Patients. In course: Making Teledermatology Work for You. Course Director: Carrie Kovarik MD. 2/16/18. Audience: Dermatology Physicians, APPs, Residents, and Students, with 75 in live attendance. American Academy of Dermatology 76th Annual Meeting (CME). San Diego, CA. 

33. An Evidenced-Based Approach to the Morbilliform Eruption. Focus Session Director. 2/17/18. Audience: Dermatology Physicians, APPs, Residents, and Students, with 140 in live attendance. American Academy of Dermatology 76th Annual Meeting (CME). San Diego, CA. 

34. Telemedicine. OSU MedNet 21 Webcast Series. 3/29/18. (CME). Columbus, OH. Audience: Live and on-demand streaming to providers in over 160 countries.

35. Dermatologic presentations, complications, and adverse events in cancer patients. OSU Arthur G. James Cancer Hospital and Emergency Department Combined Lecture Series. 4/19/18. (CME). Columbus, OH. Audience: 80 attending, resident, midlevel providers and nurses.

• Biomed Central (BMC) Cancer – Associate Editor
• Journal of the American Academy of Dermatology Case Reports – Editorial Board: Term 6/1/15-6/1/18
• Journal of the American Academy of Dermatology – Ad hoc Reviewer. 
• JAMA Dermatology – Ad hoc Reviewer

• 2013-14: National Psoriasis Foundation Fellowship. $40,000 in direct and indirect costs concurrent with residency.
  Mentor: Henry Wong MD, Ph.D. Marshall Williams Ph.D. and Maria Ariza Ph.D.
  Project: Biomarker development of human endogeneous retrovirus K dUTPase as a marker of severity, treatment, and arthritis in psoriasis patients. 
• 2015-16: American Acne and Rosacea Society, AARS. $10,000 in direct costs.
  Project: Acnes Recognition System (ARES): A low-cost, alternative acne image analysis and clinical trial scoring system.
  Role: PI.
• 2016-2018: Upper Limit Payment Advancement Awards, funded through Dept of Ohio Medicaid. $304,709 in direct costs.
  Project: Teledermatology: Improving Patient Access to Dermatology. Cultivate advanced delivery care models improving access, outcomes and lower costs for Medicaid patients.
  Role: PI. Effort 15%. 
• 2017-2018: Strategic Pharma-Academic Research Collaboration Awards, Indiana University CTSA. $99252, $119102 in direct and indirect costs.
  Project: Gene Expression and Microbiome Profiling in Hidradenitis Suppurativa to Identify Immunological Biomarkers of Disease Activity.
  Role: Site Co-PI. Effort 5%. 
• 2017-2018: National Rosacea Society, $25,000.
  Project: The use of digital image segmentation and analysis as a rosacea biomarker
  Role: PI. Effort 10%. 
• 2018-2021: Dermatology Foundation, $165,000.
  Project: Prospective Categorization and Outcomes Analysis of Cutaneous Drug Eruptions Medical Career Development Award.
  Role: PI. Effort 25%
• 2018-2019: Patient Safety Advancement Grant, OSUWMC, $25,000.
  Project: The Effect of Histopathologic  Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis.
  Role: PI. Effort NA. 

• Ohio State University Department of Internal Medicine Quality and Safety Committee: 12/14-6/17
• Ohio State University IHIS (Electronic Medical Record) Physician Steering Committee: 6/16-Present
• Patient Advocacy Committee for the American Academy of Dermatology 3/16-Present
• Ohio Dermatology Association, Young Physicians Committee, Co-Chair 11/17 -Present

• Kaffenberger BH. Gender Influences the Clinical Course of Lupus Erythematosus. PracticeUpdate website. Available at: http://www.practiceupdate.com/c/22351/1/4. Accessed April 14, 2015.
• McKinley GF, Kaffenberger BH. Blistering patch on Infant’s forearm. Clinical Advisor; May 1, 2015. 
• Kaffenberger B. The Cost of Topical Immunomodulator Therapy in Medicare Patients Varies by Prescriber Specialty. PracticeUpdate website. Available at: http://www.practiceupdate.com/content/cost-of-topical-immunomodulator-drugs-varies-by-prescriber-specialty/49563/65/4/1.

1. Kaffenberger BH, Wakely PE, Mayerson JL. / Kaffenberger BH. (2009, April). Safety of Fine-Needle Aspiration Biopsy in Diagnosis of Primary High Grade Sarcomas: A Pilot Study. Poster presented at: Ohio State University Research Day; Columbus, OH.

2. Hostetler SG, Kaffenberger B, Hostetler T, Zirwas M/Kaffenberger BH. (2009, September) The Role of Airborne Proteins and Atopic Dermatis. Poster presented at Ohio Dermatologic Association Annual Meeting 2009 in Columbus OH.

3. Hostetler SG, Kaffenberger B, Hostetler T, Zirwas M/ Kaffenberger BH. (2010, March) The Role of Airborne Proteins and Atopic Dermatis. Poster Presented at: American Academy of Dermatology Annual Meeting 2010. Miami FL.

4. Hostetler SG, Kaffenberger B, Hostetler T, Zirwas M/ Kaffenberger BH. (2010, April) The Role of Airborne Proteins and Atopic Dermatis. Poster Presented at: Ohio State University Research Day; Columbus OH.

5. Danforth D, Procter M, Heller R, Pasteur E, Chen R, Johnson M, Kaffenberger B, Fu J/Danforth D. (2010 April) Development of Virtual Patients for Medical Simulation. Poster Presented at Central Group of Educational Affairs Meeting of the American Association of Medical Colleges; Chicago IL.

6. Kaffenberger BH, Pham J, Peters S, Olencki T. Cycloxygenase-2 overexpression in the invasive edge of basal cell carcinomas: implications for further research. (2011, April). Poster Presented at: Ohio State University Research Day; Columbus OH.

7. Kaffenberger BH, Hinton A, Krishna SG. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. Abstract Presented at: Society of Dermatology Hospitalists Annual Meeting (2018, February). San Diego, CA.

1. Dangle P, Shah K, Kaffenberger B, Patel V. The Use of High Resolution Optical Coherence Tomography to Evaluate Robotic Radical Prostatectomy Specimens. Int Braz J Urol. 2009 Jun; 35(3): 344-353. 

2. Hostetler SG, Kaffenberger B, Hostetler T, Zirwas M. The Role of Airborne Proteins in Atopic Dermatis. J Clin Aesthetic Dermatol. 2010 Jan;3(1):22–31 

3. Kaffenberger BH, Wakely PE, Mayerson JL. Local Recurrence Rate of Fine-Needle Aspiration Biopsy in Primary High-Grade Sarcomas. J Surgical Onc. 2010 June; 101:618-621.

4. Kaffenberger BH, Bekaii-Saab T. Recurrent Life-threatening deep tissue hematomas after switching to generic enoxaparin: A report and perspective on the approval process of biological compounds. Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):104-6. 

5. Kaffenberger BH, Darabi K, Peters S, Kynyk J, Bechtel M. Generalized Eruptive Histiocytomas and Rosai-Dorfman disease presenting concurrently in a patient with myelodysplastic syndrome. J Clin Aesthetic Dermatol. 2012 Aug; 5(8):42-6

6. Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA. Remission of psoriasis after allogeneic, but not autologous hematopoietic stem cell transplantation. J Am Acad Dermatol. 2013 Mar;68(3):489-92

7. Wong HK, Kaffenberger BH, Zirwas M. Palpable Erythematous Cord over the back of a patient with Systemic Lupus Erythematosus. JAMA Dermatol. 2013; 149(5): 609-14. 

8. Young NA, Friedman AK, Kaffenberger B, Rajaram MVS, Birmingham DJ, Schlesinger LS, Wu L, Jarjour WN. Novel Estrogen Target Gene ZAS3 is overexpressed in Systemic Lupus Erythematosus. Mol Immunol. 2013;54(1):23-31.

9. Kaffenberger BH, Zirwas M. Comment on: “Specialty bashing during medical training: Experiences of students applying to a dermatology residency program.” J Am Acad Dermatol. 2013 Aug;69(2):314-5.

10. Madigan L, Kaffenberger BH, Wong HK. Bullae and psoriasiform hyperkeratosis following treatment with golimumab. J Am Acad Dermatol. 2013; 68(6):e195-6. 

11. Kaffenberger BH, Kaffenberger TM, Wong HK. Immunotargeting in the management of psoriasis. Immunotargets Ther. 2013; 2:51-60

12. Kaffenberger BH, Kartono-Winardi F, Frederickson J, Porcu P, Wong HK. Complete resolution of methotrexate-resistant, periorbital, primary cutaneous anaplastic large cell lymphoma with brentuximab vedotin. J Clin Aesthet Dermatol. 2013 Aug;6(8):29-31

13. Young NA, Sharma R, Friedman A, Kaffenberger BH, Bolon B, Jarjour WN. Aberrant muscle antigen exposure is sufficient to cause myositis in a regulatory T cell-deficient milieu. Arthritis Rheum. 2013; 65(12):3259-70

14. Kaffenberger BH, Lee GL, Tyler K, Chan DV, Jarjour W, Ariza ME, Williams MV, Wong HK. Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother. 2014;10(4):876-86

15. Young Nicholas A, Wu, Lai-Chu, Burd, CJ, Friedman AK, Kaffenberger BH, Rajaram MV, Schlesinger LS, James, H, Shupnik, MA, Jarjour W. Estrogen modulation of endosome-associated Toll-like receptor 8: an IFNA independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol. 2014 Mar;151(1):66-77.

16.  Kaffenberger BH, Rosenbach M. Toxic Epidermal Necrolysis and Early Transfer to a Regional Burn Unit: Is it time to reevaluate what we teach? J Am Acad Dermatol. 2014 Jul;71(1):195-6.

17. Patterson AT, Andritsos LA, Allen CM, Gru A, Kaffenberger BH. Multifocal epithelial hyperplasia (Heck disease) in a patient with chronic lymphocytic leukemia. J Cutan Pathol. 2014 Aug;41(8):694-6.

18. Kaffenberger BH, Kaffenberger JA, Zirwas M.  Academic dermatologists’ views on the value of residency letters of recommendation. J Am Acad Dermatol. 2014 Aug;71(2):395-6

19. Ulman CA, Kaffenberger BH, Plotner A. An Enlarging Fluctuant Mass of the scalp. J Am Acad Dermatol. 2014; 71(6):e235-6 

20. Kaffenberger BH, Mathis J, Zirwas M. A retrospective descriptive study of azole antifungals in patch test negative head and neck atopic dermatitis. J Am Acad Dermatol. 2014 Sep;71(3):480-3. 

21.  Kaffenberger BH, Zuo RC, Gru A, Plotner A, Sweeney SA, Devine SM, Hymes SR, Cowen E. Graft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity. J Am Acad Dermatol. 2014 Oct;71(4):745-53.

22.  Kaffenberger BH, Fabbro SK, Harfmann KL. Resident Rounds part I. Program Spotlight: Ohio State University. J Drugs Dermatol. 2014; 13(8):980-1

23. Fabbro SK, Kaffenberger BH. Resident Rounds part II: HIV Dermatoses. J Drugs Dermatol. 2014; 13(8):987-9.

24. Fabbro SK, Kaffenberger BH. Resident rounds part III: plasma cell leukemia with initial cutaneous presentation. J Drugs Dermatol. 2014 Aug;13(8):994-5

25. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar. Ibrutinib treatment ameliorates murine chronic Graft-Versus-Host Disease.  J Clin Invest. 2014; 124(11):4867-76

26. Young NA, Wu LC, Bruss M, Kaffenberger BH, Hampton J, Bolon B, Jarjour WN. A chimeric human-mouse model of Sjögren's syndrome. 2015 Jan;156(1):1-8.

27. Mathis J, Zirwas MJ, Elkins CT, Bechtel MA, Kaffenberger BH. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (Hypergammaglobulinemic Purpura of Waldenström). J Am Acad Dermatol. 2015 Feb;72(2):374-6

28. Kaffenberger B, Haverkos B, Tyler K, Wong HK, Porcu P, Gru AA. Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder. Am J Dermatopathol. 2015 Aug;37(8):604-13 PMID 25839892

29. Kaffenberger BH, Kaffenberger JA, Wong H, Jarjour WN, Levin D, Bechtel MA. Magnetic resonance elastography and transient elastography as noninvasive analyses for liver fibrosis: can they obviate the liver biopsy in psoriasis patients treated with methotrexate? Int J Dermatol. 2015;54(7):752-6. 

30. McLaughlin CT, Kaffenberger BH, Gru AA. A hybrid tumor with schwannoma-perineuroma-neurofibroma morphology. J Cutan Pathol.  2015 Nov;42(11):911-3

31. Patterson AT, Tian FT, Elston DM, Kaffenberger BH. Occluded Cigarette Smoke Exposure Causing Localized Chloracne-Like Comedones. Dermatology. 2015;231(4):322-5.

32. Patterson AT, Kaffenberger BH, Keller RA, Elston DM. Skin diseases associated with Agent Orange and other organochlorine exposures. J Am Acad Dermatol.  2016 Jan;74(1):143-70

33. McKinley GF, Kaffenberger BH. 
Recurrent desquamative vulvovaginitis in a young woman. Int J Dermatol. 2016 Jan;55(1):21-3.

34. Duncan JR, Kaffenberger BH, Gru A. The necessity of clinicopathologic correlation: syphilis that could have been missed. J Cutan Pathol.  2016 Mar;43(3):295-7

35. Patel TR, Kaffenberger BH, Gru AA. An Unusual Growth on the Nipple. Am J Dermatopathol. 2017 Mar;39(3):195-196 PMID:26488719

36. Smith SM, Salavaggione AL, Kaffenberger BH, Gru AA. Follicular Induction Changes Overlying a Melanocytic Nevus. Am J Dermatopathol. 2016 Mar;38(3):246-7.  PMID: 26355763

37. Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA. Endothelial chimerism in chronic sclerotic-type chronic Graft-versus-Host disease and GVHD-associated angiomatosis. Br J Dermatol. 2016 Oct;175(4):782-4 PMID: 26875995

38. Haraldsdottir S, Bertino E, Haglund K, Kaffenberger B, Shah MH. Radiation Recall Dermatitis With Concomitant Dabrafenib and Pazopanib Therapy. JAMA Dermatol. 2016 May 1;152(5):587-9. PMID:26886900

39. Hibler J, Ojong O, Kaffenberger BH. Acquired Port-Wine Stain (Fegeler’s Syndrome): A Case Report and Literature Review. J Am Osteopath Col Dermatol. 2016; 35:15-16

40. Duncan JR, Kaffenberger BH, Gru A. Perianal Tumor With Overlap Features of Fibroadenoma and Phyllodes Tumor Arising From Anogenital Mammary-like Glands. Am J Dermatopathol. 2016 Aug;38(8):639-42

41. Duncan JR, Carr D, Kaffenberger BH. The utility of positron emission tomography with and without computed tomography in patients with nonmelanoma skin cancer. J Am Acad Dermatol. 2016 Jul;75(1):186-96. PMID: 26992283

42. Vaynshtok P, Tian F, Kaffenberger BH. Acitretin amelioration of acrokeratosis paraneoplastica (Bazex Syndrome) in cases of incurable squamous cell carcinoma of the hypopharynx. Dermatol Online J. 2016 Sep 15;22(9). pii: 13030/qt8n96v45x. PMID: 28329620

43. Tian, F., Patterson AT, Davick JJ, Ing SW, Kaffenberger BH, Gru AA. The cutaneous expression of vitamin K-dependent and other osteogenic proteins in calciphylaxis stratified by clinical features and warfarin use: A case control study. J Am Acad Dermatol. 2016. 75(4), 840–842. 

44. Saultz JN, Kaffenberger BH, Taylor M, Heerema NA, Klisovic R. Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. JAMA Dermatol. 2016 Dec 1;152(12):1391-1393

45. Kaffenberger BH, Shetlar D, Norton S, Rosenbach M. The effect of climate change on skin disease in North America. J Am Acad Dermatol. 2017 Jan;76(1):140-147, PMID: 27742170

46. Kaffenberger JA, Mosser J, Lee G, Pootrakul L, Harfmann K, Fabbro S, Faith EF, Carr D, Plotner A, Zirwas M, Kaffenberger BH. A Retrospective Analysis Comparing the New Standardized Letter of Recommendation in Dermatology with the Classic Narrative Letter of Recommendation. J Clin Aesthet Dermatol. 2016 Sep;9(9):36-42.

47. Korman AM, Hastings JG, Byrd JC, Kaffenberger BH. Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia. JAMA Dermatol. 2017 Jan 1;153(1):108-110, PMID:27892987

48. Li F, Kaffenberger B, Hart PA. An Unusual Rash During Evaluation for Chronic Pancreatitis. Gastroenterology. 2017 Jan;152(1):e4-e5

49. Smith SM, Milam PB, Fabbro SK, Gru AA, Kaffenberger BH. Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition. JAAD Case Rep. 2016 Dec 7;2(6):476-481. PMID: 27981223

50. Korman AM, Tyler KH, Kaffenberger, BH. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma. Int J Dermatol. 2017. Apr;56(4):e75-e77 PMID 28102540

51. Korman AM, Alikhan A, Kaffenberger BH.  Viral Exanthems: An update on laboratory testing of the adult patient. J Am Acad Dermatol. 2017 Mar;76(3):538-550, PMID 28413059

52.  Zhang M, Silverberg JI, Kaffenberger BH. The cost of topical immunomodulator therapy in Medicare patients varies by prescriber specialty. J Am Acad Dermatol. 2017 May;76(5):925-931. PMID: 28162853

53. Gupta P, Shin T, Sopkovich J, Massick S, Kaffenberger BH. Generic twice daily minocycline versus branded extended release minocycline for acne: a retrospective comparison of treatment excalation. J Am Acad Dermatol. 2017; 76(6):1195-7

54. Milani-Nejad N, Zhang M, Kaffenberger BH. Association of Dermatology Consults with Patient Care Outcomes in Hospitalized Patients with Inflammatory Skin Disease. JAMA Dermatol.  2017 Jun 1;153(6):523-528. PMID: 28296992

55. Milani-Nejad N, Tyler K, Grieco C, Kaffenberger BH. Pasteurella Multocida Ecthyma Complicated by Necrotizing Fasciitis. Dermatol Online J. 2017 Apr; 23(4):5

56. Zhang M, Silverberg JI, Kaffenberger BH. Prescription patterns and cost of acne/rosacea medications in Medicare population vary by prescriber specialty. J Am Acad Dermatol. 2017, 77(3):448-455. PMID:28651825

57. Kalik JA, Friedman H, Bechtel MA, Gru AA, Kaffenberger BH. Purpura Annularis Telangiectodes of Majocchi Associated With the Initiation and Rechallenge of Apremilast for Psoriasis Vulgaris. JAMA Dermatol.  2017 Nov 1;153(11):1197-1198. PMID:28793154

58. Milam PB, Vasu SV, Gru AA, Kaffenberger BH. Psoriasiform graft-versus-host disease distributed along Blaschko's lines. J Cutan Pathol. 2017 Oct;44(10):882-886. PMID:2865516

59. Dean SM, Kaffenberger BH, Lustberg ME. Kaposi sarcoma: An unconventional cause of lower extremity lymphedema. Vasc Med. . 2017 Dec;22(6):544. PMID:28875759

60. Tian F, Mazurek KR, Malinak RN, Dean SM, Kaffenberger BH. Pseudocellulitis Need Not be Benign: Three Cases of Superficial Migratory Thrombophlebitis with “Negative” Venous Duplex Ultrasonography. J Clin 
Aesthet Dermatol. 2017; 10(12)49-51. 

61. Wang RF, Kaffenberger BH, Kaffenberger JA. A Retrospective Review of New-onset Dermatitis in Patients Aged 60 Years or Older. J Clin Aesthet Dermatol. 2018 Jan;11(1):19-20. PMID 29410725

62. Kaffenberger BH, Hinton A, Krishna S. The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey. J Am Acad Dermatol. 2018 Feb 10. pii: S0190-9622(18)30184-1. doi: 10.1016/j.jaad.2018.02.007. PMID 29438762

63. Kaffenberger BH, Trinidad J. Diagnosis uPGrade-Advances in Pyoderma Gangrenosum. JAMA Dermatol. 2018 Feb 14. doi: 10.1001/jamadermatol.2017.5979. PMID: 29450448

64. Tolliver S, Graham J, Kaffenberger BH. A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema. Int J Dermatol. 2018 Feb 16. doi: 10.1111/ijd.13947. PMID: 29450880

65. Ridpath AV, Rzepka PV, Shearer SM, Scrape SR, Olencki TE, Kaffenberger BH. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid. Int J Dermatol. 2018 Apr 6. doi: 10.1111/ijd.13970. PMID: 29624655

• Dermatology Free Clinic: 04/ 2009- Present. Columbus Ohio. Physician Volunteer 
• Ohio State University College of Medicine Admissions Committee: 08/ 2008 - 4/2010. Columbus, OH